A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.
Checked against the public recordLast updated Feb 28, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Incyte Corporation
- Interventions being studied
- Drug: Epacadostat; Drug: Nivolumab; Drug: Ipilimumab; Drug: Lirilumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * During Phase 1, participant with locally advanced or metastatic solid tumors with disease progression on or after treatment with available therapies, or who are intolerant to treatment, or who refuse standard treatment. * During Phase 2, participant with advanced cancer who have received at least one prior therapy or are treatment naive, depending on the specified tumor type. * Presence of measurable disease per RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Expected survival of ≥ 12 weeks. Exclusion Criteria: * Laboratory and medical history parameters not within the Protocol-defined range. * Receipt of anticancer medications or investigational drugs within Protocol-defined time frames. * Previous radiotherapy within 7 days of Cycle 1 Day 1. * Known active central nervous system metastases and/or carcinomatous meningitis. * Prior treatment with any immune checkpoint inhibitor and/or an IDO inhibitor. * Active infection requiring systemic therapy. * Any active or inactive autoimmune disease or syndrome
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Alabama at BirminghamBirmingham, Alabama
- The Angeles Clinic and Research InstituteLos Angeles, California
- John Wayne Cancer InstituteSanta Monica, California
- Duke University Medical CenterDurham, North Carolina
- Vanderbilt University Medical CenterNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 28, 2022. Always confirm current availability with the study team.